Recruiting | Phase II
Testing The Addition Of Chemotherapy Drug, Cisplatin, To Usual Radiation Therapy For Patients With Head And Neck Cancer
To compare two treatment approaches currently used after surgery for head and neck cancer. One approach is to administer radiation therapy alone. A second approach is to administer radiation therapy along with the chemotherapy drug, cisplatin.
Before study initiation, a laboratory test to determine the genomic mutation of the TP53 gene is mandatory. This will be accomplished by testing small pieces of cancer tissue from prior surgery.
Group 1: Radiation therapy (usual approach group)
Group 2: Radiation therapy plus cisplatin (study group)
Key Participation Requirements:
Female and Male
19 years and older
Squamous cell carcinoma of the head/neck
Verrucous carcinoma of the head/neck
Spindle cell carcinoma of the head/neck
Carcinoma NOS of the head/neck (oral cavity, oropharynx, hypopharynx or larynx)
Pathologic stage III or IVA
Has had surgery to remove the primary tumor
No chemotherapy within 2 years of surgical removal of tumor
Patients must sign an approved informed consent and authorization permitting release of personal health information.
Methodist Health System Trial Code:
For more information, visit the U.S. National Library of Medicine clinical trial database.